CVS settles with FTC, agrees to count TrumpRx drug purchases towards insurance | Reuters

CVS Caremark settles with the FTC, agreeing to count TrumpRx purchases toward insurance deductibles, eliminate rebate-based pricing models, and cap insulin out-of-pocket costs at $25/month. The settlement mirrors earlier enforcement against Cigna and Express Scripts, and regulators estimate it will save billions on drug prices.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.